Lapatinib and ixempra

Phase 1Small molecule

HHung-Hsueh Chou

Lapatinib and ixempra is one of 52 small molecule programs targeting Endometrial Carcinoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Endometrial CarcinomaActive, not recruiting

Endometrial CarcinomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

62 competitors in Endometrial Carcinoma

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 3

6 2

Lenvima

Eisai

Phase 3

5 3

Depo-Provera

Eli Lilly

Phase 3

1 4

Paraplatin

AAvyxa

Phase 3

6 5

Xpovio

KKaryopharm Therapeutics Inc

Phase 3

1 6

Herceptin

OOrganon and Co

Phase 3

1 7

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

1 8

Keytruda

Merck & Co.

Phase 2

5 9

Megace

Bristol-Myers Squibb

Phase 2

3 10

Femara

Novartis

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Endometrial Carcinoma1 trial

A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma

Unknown status·HHung-Hsueh Chou·Phase 1·NCT01454479·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Lapatinib and ixempra. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lapatinib and ixempra compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lapatinib and ixempra. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hung-Hsueh Chou company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: HHung-Hsueh Chou

Lapatinib and ixempra

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Endometrial Carcinoma1 trial

References

Drug Info

Quick Facts

Related News